- This topic has 2 replies, 2 voices, and was last updated 5 months, 3 weeks ago by
.
-
Posts
-
-
“Researchers identify a cellular defect common to familial and sporadic forms of ALS”
A recent NIH-funded study may point to a possible therapeutic target for the disease.
Read the announcement here:
What do you think of this breakthrough? Does it hold promise for ALS patients? Especially when it identifies a cell defect that is shown to be common in both sporadic and familial ALS.
-
This is where it gets interesting;
” If an antisense oligonucleotide drug, which stops cells from manufacturing specific proteins, was used to decrease the amount of CHMP7 within the ALS neurons, the pore never degraded. “
-
If past history of so-called ALS treatment breakthroughs are any indication of any possible future ALS treatments, then this too will fizzy out into obscurity.
Richard
-
Dr. Rothstein works in ALS research since a long time (~20 years?). But what is presented here is not very impressive. Working with iPSC-derived is something that could be done at little cost now, and (fortunately) many teams are working on ways to mitigate TDP-43 aggregates.
And it only pushes the goal post further away: What makes CHMP7 aggregate in the nucleus?I guess this work has two objectives:
1. Participating in the run to patent TDP-43 therapies.
2. Showing to funding parties that the lab is doing something with their money.
-
-
- You must be logged in to reply to this topic.
